Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 11/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17986129 | 1.00 | KCNJ1 (0.45) | KCNJ1SIGMAR1KCNH2CCR2HRH3 | |
| SCHEMBL17985855 | 0.96 | KCNJ1 (0.48) | KCNJ1SIGMAR1KCNH2CCR2HRH3 | |
| SCHEMBL3249763 | 0.93 | KCNJ1 (0.46) | KCNJ1SIGMAR1KCNH2CCR2HRH3 | |
| SCHEMBL3769255 | 0.93 | KCNJ1 (0.46) | KCNJ1SIGMAR1KCNH2CCR2HRH3 | |
| SCHEMBL18021193 | 0.92 | SIGMAR1 (0.45) | KCNJ1SIGMAR1KCNH2CCR2HRH3 | |
| SCHEMBL18021203 | 0.92 | SIGMAR1 (0.45) | KCNJ1SIGMAR1KCNH2CCR2HRH3 | |
| SCHEMBL13014130 | 0.90 | KCNJ1 (0.45) | KCNJ1SIGMAR1KCNH2HRH3 | |
| SCHEMBL13014054 | 0.90 | KCNJ1 (0.45) | KCNJ1SIGMAR1KCNH2HRH3 | |
| SCHEMBL18021195 | 0.90 | SIGMAR1 (0.45) | KCNJ1SIGMAR1KCNH2CCR5 | |
| SCHEMBL18021169 | 0.89 | SIGMAR1 (0.41) | KCNJ1SIGMAR1KCNH2CCR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | UNIV ANTWERPEN (BE) | 2025-11-06 | — | — | US | disclosed |
| EP-4531932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Universiteit Antwerpen (BE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025037000-A1 | NOVEL FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND MEDICAL USES THEREOF | UNIVERSITEIT ANTWERPEN (BE) | 2025-02-20 | — | — | WO | disclosed |
| WO-2023233023-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | UNIVERSITEIT ANTWERPEN (BE) | 2023-12-07 | — | — | WO | disclosed |
| US-10842893-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10842893-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10441669-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-10-15 | — | — | US | disclosed |
| US-10441669-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20160235870-A1 | MULTIFUNCTIONAL CHELATORS, COMPLEXES, AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2016-08-18 | — | — | US | disclosed |
| US-20160235870-A1 | MULTIFUNCTIONAL CHELATORS, COMPLEXES, AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2015051362-A1 | MULTIFUNCTIONAL CHELATORS, COMPLEXES, AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | ILLINOIS INSTITUTE OF TECHNOLOGY (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FIBP, FGF1, FGFR1 | KCNJ1 4440/4885SIGMAR1 4860/4885KCNH2 4619/4885 |
| US-10842893-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | FECH, SLC40A1, TFRC | KCNJ1 3900/4885SIGMAR1 1930/4885KCNH2 4384/4885 |
| US-20160235870-A1 | MULTIFUNCTIONAL CHELATORS, COMPLEXES, AND COMPOSITIONS THEREOF, AND METHODS OF USING SAME | FECH, SLC40A1, TFRC | KCNJ1 3900/4885SIGMAR1 1930/4885KCNH2 4384/4885 |
| US-10441669-B2 | Multifunctional chelators, complexes, and compositions thereof, and methods of using same | FECH, SLC40A1, TFRC | KCNJ1 3900/4885SIGMAR1 1930/4885KCNH2 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.